Abstract
Immunotherapy entails the treatment of disease by modulation of the immune system. As detailed in the previous chapters, the different modes of achieving immune modulation are many, including the use of small/large molecules, cellular therapy, and radiation. Oncolytic viruses that can specifically attack, replicate within, and destroy tumors represent one of the most promising classes of agents for cancer immunotherapy (recently termed as oncolytic immunotherapy). The notion of oncolytic immunotherapy is considered as the way in which virus-induced tumor cell death (known as immunogenic cancer cell death (ICD)) allows the immune system to recognize tumor cells and provide long-lasting antitumor immunity. Both immune responses toward the virus and ICD together contribute toward successful antitumor efficacy. What is now becoming increasingly clear is that monotherapies, through any of the modalities detailed in this book, are neither sufficient in eradicating tumors nor in providing long-lasting antitumor immune responses and that combination therapies may deliver enhanced efficacy. After the rise of the genetic engineering era, it has been possible to engineer viruses to harbor combination-like characteristics to enhance their potency in cancer immunotherapy. This chapter provides a historical background on oncolytic virotherapy and its future application in cancer immunotherapy, especially as a combination therapy with other treatment modalities.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Alain, T., Lun, X., Martineau, Y., Sean, P., Pulendran, B., Petroulakis, E., Zemp, F. J., Lemay, C. G., Roy, D., Bell, J. C., Thomas, G., Kozma, S. C., Forsyth, P. A., Costa-Mattioli, M., & Sonenberg, N. (2010). Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production. Proceedings of the National Academy of Sciences of the United States of America, 107(4), 1576–1581.
Alvarez-Breckenridge, C., Kaur, B., & Chiocca, E. A. (2009). Pharmacologic and chemical adjuvants in tumor virotherapy. Chemical Reviews, 109(7), 3125–3140.
Alvarez-Breckenridge, C. A., Yu, J., Caligiuri, M. A., & Chiocca, E. A. (2013). Uncovering a novel mechanism whereby NK cells interfere with glioblastoma virotherapy. Oncoimmunology, 2(4), e23658.
Andtbacka, R. H., Kaufman, H. L., Collichio, F., Amatruda, T., Senzer, N., Chesney, J., Delman, K. A., Spitler, L. E., Puzanov, I., Agarwala, S. S., Milhem, M., Cranmer, L., Curti, B., Lewis, K., Ross, M., Guthrie, T., Linette, G. P., Daniels, G. A., Harrington, K., Middleton, M. R., Miller, W. H., Jr., Zager, J. S., Ye, Y., Yao, B., Li, A., Doleman, S., VanderWalde, A., Gansert, J., & Coffin, R. (2015). Talimogene Laherparepvec improves durable response rate in patients with advanced melanoma. Journal of Clinical Oncology, 33(25), 2780–2788.
Armstrong, L., Arrington, A., Han, J., Gavrikova, T., Brown, E., Yamamoto, M., Vickers, S. M., & Davydova, J. (2012). Generation of a novel, cyclooxygenase-2-targeted, interferon-expressing, conditionally replicative adenovirus for pancreatic cancer therapy. American Journal of Surgery, 204(5), 741–750.
Asada, T. (1974). Treatment of human cancer with mumps virus. Cancer, 34(6), 1907–1928.
Bai, F., Niu, Z., Tian, H., Li, S., Lv, Z., Zhang, T., Ren, G., & Li, D. (2014). Genetically engineered Newcastle disease virus expressing interleukin 2 is a potential drug candidate for cancer immunotherapy. Immunology Letters, 159(1–2), 36–46.
Barker, D. D., & Berk, A. J. (1987). Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. Virology, 156(1), 107–121.
Bartlett, D. L., Liu, Z., Sathaiah, M., Ravindranathan, R., Guo, Z., He, Y., & Guo, Z. S. (2013). Oncolytic viruses as therapeutic cancer vaccines. Molecular Cancer, 12(1), 103.
Bauzon, M., & Hermiston, T. W. (2012). Oncolytic viruses: The power of directed evolution. Advances in Virology, 2012, 586389.
Bergman, I., Griffin, J. A., Gao, Y., & Whitaker-Dowling, P. (2007). Treatment of implanted mammary tumors with recombinant vesicular stomatitis virus targeted to Her2/neu. International Journal of Cancer Journal International du Cancer, 121(2), 425–430.
Bernt, K. M., Ni, S., Tieu, A. T., & Lieber, A. (2005). Assessment of a combined, adenovirus-mediated oncolytic and immunostimulatory tumor therapy. Cancer Research, 65(10), 4343–4352.
Beug, S. T., Tang, V. A., LaCasse, E. C., Cheung, H. H., Beauregard, C. E., Brun, J., Nuyens, J. P., Earl, N., St-Jean, M., Holbrook, J., Dastidar, H., Mahoney, D. J., Ilkow, C., Le Boeuf, F., Bell, J. C., & Korneluk, R. G. (2014). Smac mimetics and innate immune stimuli synergize to promote tumor death. Nature Biotechnology, 32(2), 182–190.
Beyer, M., Kochanek, M., Darabi, K., Popov, A., Jensen, M., Endl, E., Knolle, P. A., Thomas, R. K., von Bergwelt-Baildon, M., Debey, S., Hallek, M., & Schultze, J. L. (2005). Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood, 106(6), 2018–2025.
Bianchi, M. E. (2007). DAMPs, PAMPs and alarmins: All we need to know about danger. Journal of Leukocyte Biology, 81(1), 1–5.
Bierman, H. R., Crile, D. M., Dod, K. S., Kelly, K. H., Petrakis, N. L., White, L. P., & Shimkin, M. B. (1953). Remissions in leukemia of childhood following acute infectious disease: Staphylococcus and streptococcus, varicella, and feline panleukopenia. Cancer, 6(3), 591–605.
Binder, C., Hagemann, T., Husen, B., Schulz, M., & Einspanier, A. (2002). Relaxin enhances in-vitro invasiveness of breast cancer cell lines by up-regulation of matrix metalloproteases. Molecular Human Reproduction, 8(9), 789–796.
Binder, D. C., Fu, Y. X., & Weichselbaum, R. R. (2015). Radiotherapy and immune checkpoint blockade: Potential interactions and future directions. Trends in Molecular Medicine, 21(8), 463–465.
Bischoff, J. R., Kirn, D. H., Williams, A., Heise, C., Horn, S., Muna, M., Ng, L., Nye, J. A., Sampson-Johannes, A., Fattaey, A., & McCormick, F. (1996). An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science, 274(5286), 373–376.
Blackham, A. U., Northrup, S. A., Willingham, M., D’Agostino, R. B., Jr., Lyles, D. S., & Stewart, J. H. (2013). Variation in susceptibility of human malignant melanomas to oncolytic vesicular stomatitis virus. Surgery, 153(3), 333–343.
Bluming, A. Z., & Ziegler, J. L. (1971). Regression of Burkitt’s lymphoma in association with measles infection. Lancet, 2(7715), 105–106.
Bolyard, C., Yoo, J. Y., Wang, P. Y., Saini, U., Rath, K. S., Cripe, T. P., Zhang, J., Selvendiran, K., & Kaur, B. (2014). Doxorubicin synergizes with 34.5ENVE to enhance antitumor efficacy against metastatic ovarian cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 20(24), 6479–6494.
Breitbach, C. J., Burke, J., Jonker, D., Stephenson, J., Haas, A. R., Chow, L. Q., Nieva, J., Hwang, T. H., Moon, A., Patt, R., Pelusio, A., Le Boeuf, F., Burns, J., Evgin, L., De Silva, N., Cvancic, S., Robertson, T., Je, J. E., Lee, Y. S., Parato, K., Diallo, J. S., Fenster, A., Daneshmand, M., Bell, J. C., & Kirn, D. H. (2011). Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature, 477(7362), 99–102.
Bridle, B. W., Chen, L., Lemay, C. G., Diallo, J. S., Pol, J., Nguyen, A., Capretta, A., He, R., Bramson, J. L., Bell, J. C., Lichty, B. D., & Wan, Y. (2013). HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy. Molecular Therapy: The Journal of the American Society of Gene Therapy, 21(4), 887–894.
Buckel, L., Advani, S. J., Frentzen, A., Zhang, Q., Yu, Y. A., Chen, N. G., Ehrig, K., Stritzker, J., Mundt, A. J., & Szalay, A. A. (2013). Combination of fractionated irradiation with anti-VEGF expressing vaccinia virus therapy enhances tumor control by simultaneous radiosensitization of tumor associated endothelium. International Journal of Cancer Journal International du Cancer, 133(12), 2989–2999.
Buonaguro, F. M., Tornesello, M. L., Izzo, F., & Buonaguro, L. (2012). Oncolytic virus therapies. Pharmaceutical Patent Analyst, 1(5), 621–627.
Burke, J. M., Lamm, D. L., Meng, M. V., Nemunaitis, J. J., Stephenson, J. J., Arseneau, J. C., Aimi, J., Lerner, S., Yeung, A. W., Kazarian, T., Maslyar, D. J., & McKiernan, J. M. (2012). A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer. The Journal of Urology, 188(6), 2391–2397.
Carew, J. F., Kooby, D. A., Halterman, M. W., Kim, S. H., Federoff, H. J., & Fong, Y. (2001). A novel approach to cancer therapy using an oncolytic herpes virus to package amplicons containing cytokine genes. Molecular Therapy: The Journal of the American Society of Gene Therapy, 4(3), 250–256.
Cascallo, M., Alonso, M. M., Rojas, J. J., Perez-Gimenez, A., Fueyo, J., & Alemany, R. (2007). Systemic toxicity-efficacy profile of ICOVIR-5, a potent and selective oncolytic adenovirus based on the pRB pathway. Molecular Therapy: The Journal of the American Society of Gene Therapy, 15(9), 1607–1615.
Cassel, W. A., & Garrett, R. E. (1965). Newcastle disease virus as an antineoplastic agent. Cancer, 18, 863–868.
Cassel, W. A., & Garrett, R. E. (1966). Tumor immunity after viral oncolysis. Journal of Bacteriology, 92(3), 792.
Cassel, W. A., & Murray, D. R. (1992). A ten-year follow-up on stage II malignant melanoma patients treated postsurgically with Newcastle disease virus oncolysate. Medical Oncology and Tumor Pharmacotherapy, 9(4), 169–171.
Cattaneo, R., Miest, T., Shashkova, E. V., & Barry, M. A. (2008). Reprogrammed viruses as cancer therapeutics: Targeted, armed and shielded. Nature Reviews Microbiology, 6(7), 529–540.
Cerullo, V., Pesonen, S., Diaconu, I., Escutenaire, S., Arstila, P. T., Ugolini, M., Nokisalmi, P., Raki, M., Laasonen, L., Sarkioja, M., Rajecki, M., Kangasniemi, L., Guse, K., Helminen, A., Ahtiainen, L., Ristimaki, A., Raisanen-Sokolowski, A., Haavisto, E., Oksanen, M., Karli, E., Karioja-Kallio, A., Holm, S. L., Kouri, M., Joensuu, T., Kanerva, A., & Hemminki, A. (2010). Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. Cancer Research, 70(11), 4297–4309.
Cerullo, V., Diaconu, I., Kangasniemi, L., Rajecki, M., Escutenaire, S., Koski, A., Romano, V., Rouvinen, N., Tuuminen, T., Laasonen, L., Partanen, K., Kauppinen, S., Joensuu, T., Oksanen, M., Holm, S. L., Haavisto, E., Karioja-Kallio, A., Kanerva, A., Pesonen, S., Arstila, P. T., & Hemminki, A. (2011). Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus. Molecular Therapy: The Journal of the American Society of Gene Therapy, 19(9), 1737–1746.
Chase, M., Chung, R. Y., & Chiocca, E. A. (1998). An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy. Nature Biotechnology, 16(5), 444–448.
Chen, D. S., & Mellman, I. (2013). Oncology meets immunology: The cancer-immunity cycle. Immunity, 39(1), 1–10.
Chen, Y., Yu, D. C., Charlton, D., & Henderson, D. R. (2000). Pre-existent adenovirus antibody inhibits systemic toxicity and antitumor activity of CN706 in the nude mouse LNCaP xenograft model: Implications and proposals for human therapy. Human Gene Therapy, 11(11), 1553–1567.
Chen, Y., DeWeese, T., Dilley, J., Zhang, Y., Li, Y., Ramesh, N., Lee, J., Pennathur-Das, R., Radzyminski, J., Wypych, J., Brignetti, D., Scott, S., Stephens, J., Karpf, D. B., Henderson, D. R., & Yu, D. C. (2001). CV706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity. Cancer Research, 61(14), 5453–5460.
Chiocca, E. A., Abbed, K. M., Tatter, S., Louis, D. N., Hochberg, F. H., Barker, F., Kracher, J., Grossman, S. A., Fisher, J. D., Carson, K., Rosenblum, M., Mikkelsen, T., Olson, J., Markert, J., Rosenfeld, S., Nabors, L. B., Brem, S., Phuphanich, S., Freeman, S., Kaplan, R., & Zwiebel, J. (2004). A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Molecular Therapy: The Journal of the American Society of Gene Therapy, 10(5), 958–966.
Choi, K. J., Kim, J. H., Lee, Y. S., Kim, J., Suh, B. S., Kim, H., Cho, S., Sohn, J. H., Kim, G. E., & Yun, C. O. (2006). Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect. Gene Therapy, 13(13), 1010–1020.
Choi, I. K., Lee, J. S., Zhang, S. N., Park, J., Sonn, C. H., Lee, K. M., & Yun, C. O. (2011). Oncolytic adenovirus co-expressing IL-12 and IL-18 improves tumor-specific immunity via differentiation of T cells expressing IL-12Rbeta2 or IL-18Ralpha. Gene Therapy, 18(9), 898–909.
Choi, K. J., Zhang, S. N., Choi, I. K., Kim, J. S., & Yun, C. O. (2012). Strengthening of antitumor immune memory and prevention of thymic atrophy mediated by adenovirus expressing IL-12 and GM-CSF. Gene Therapy, 19(7), 711–723.
Choi, I. K., Li, Y., Oh, E., Kim, J., & Yun, C. O. (2013). Oncolytic adenovirus expressing IL-23 and p35 elicits IFN-gamma- and TNF-alpha-co-producing T cell-mediated antitumor immunity. PLoS One, 8(7), e67512.
Cody, J. J., Scaturro, P., Cantor, A. B., Yancey Gillespie, G., Parker, J. N., & Markert, J. M. (2012). Preclinical evaluation of oncolytic deltagamma(1)34.5 herpes simplex virus expressing interleukin-12 for therapy of breast cancer brain metastases. International Journal of Breast Cancer, 2012, 628697.
Coen, D. M., Kosz-Vnenchak, M., Jacobson, J. G., Leib, D. A., Bogard, C. L., Schaffer, P. A., Tyler, K. L., & Knipe, D. M. (1989). Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate. Proceedings of the National Academy of Sciences of the United States of America, 86(12), 4736–4740.
Coukos, G., Makrigiannakis, A., Kang, E. H., Caparelli, D., Benjamin, I., Kaiser, L. R., Rubin, S. C., Albelda, S. M., & Molnar-Kimber, K. L. (1999). Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 5(6), 1523–1537.
Currier, M. A., Eshun, F. K., Sholl, A., Chernoguz, A., Crawford, K., Divanovic, S., Boon, L., Goins, W. F., Frischer, J. S., Collins, M. H., Leddon, J. L., Baird, W. H., Haseley, A., Streby, K. A., Wang, P. Y., Hendrickson, B. W., Brekken, R. A., Kaur, B., Hildeman, D., & Cripe, T. P. (2013). VEGF blockade enables oncolytic cancer virotherapy in part by modulating intratumoral myeloid cells. Molecular Therapy: The Journal of the American Society of Gene Therapy, 21(5), 1014–1023.
Dengjel, J., Schoor, O., Fischer, R., Reich, M., Kraus, M., Muller, M., Kreymborg, K., Altenberend, F., Brandenburg, J., Kalbacher, H., Brock, R., Driessen, C., Rammensee, H. G., & Stevanovic, S. (2005). Autophagy promotes MHC class II presentation of peptides from intracellular source proteins. Proceedings of the National Academy of Sciences of the United States of America, 102(22), 7922–7927.
DeWeese, T. L., van der Poel, H., Li, S., Mikhak, B., Drew, R., Goemann, M., Hamper, U., DeJong, R., Detorie, N., Rodriguez, R., Haulk, T., DeMarzo, A. M., Piantadosi, S., Yu, D. C., Chen, Y., Henderson, D. R., Carducci, M. A., Nelson, W. G., & Simons, J. W. (2001). A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Research, 61(20), 7464–7472.
Diallo, J. S., Le Boeuf, F., Lai, F., Cox, J., Vaha-Koskela, M., Abdelbary, H., MacTavish, H., Waite, K., Falls, T., Wang, J., Brown, R., Blanchard, J. E., Brown, E. D., Kirn, D. H., Hiscott, J., Atkins, H., Lichty, B. D., & Bell, J. C. (2010). A high-throughput pharmacoviral approach identifies novel oncolytic virus sensitizers. Molecular Therapy: The Journal of the American Society of Gene Therapy, 18(6), 1123–1129.
Dias, J. D., Hemminki, O., Diaconu, I., Hirvinen, M., Bonetti, A., Guse, K., Escutenaire, S., Kanerva, A., Pesonen, S., Loskog, A., Cerullo, V., & Hemminki, A. (2012). Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4. Gene Therapy, 19(10), 988–998.
Dilley, J., Reddy, S., Ko, D., Nguyen, N., Rojas, G., Working, P., & Yu, D. C. (2005). Oncolytic adenovirus CG7870 in combination with radiation demonstrates synergistic enhancements of antitumor efficacy without loss of specificity. Cancer Gene Therapy, 12(8), 715–722.
Dock, G. (1904). The influence of complicating diseases upon leukaemia. American Journal of the Medical Sciences, 127, 563–592.
Dong, F., Wang, L., Davis, J. J., Hu, W., Zhang, L., Guo, W., Teraishi, F., Ji, L., & Fang, B. (2006). Eliminating established tumor in nu/nu nude mice by a tumor necrosis factor-alpha-related apoptosis-inducing ligand-armed oncolytic adenovirus. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 12(17), 5224–5230.
Du, T., Shi, G., Li, Y. M., Zhang, J. F., Tian, H. W., Wei, Y. Q., Deng, H., & Yu, D. C. (2014). Tumor-specific oncolytic adenoviruses expressing granulocyte macrophage colony-stimulating factor or anti-CTLA4 antibody for the treatment of cancers. Cancer Gene Therapy, 21(8), 340–348.
Duntsch, C. D., Zhou, Q., Jayakar, H. R., Weimar, J. D., Robertson, J. H., Pfeffer, L. M., Wang, L., Xiang, Z., & Whitt, M. A. (2004). Recombinant vesicular stomatitis virus vectors as oncolytic agents in the treatment of high-grade gliomas in an organotypic brain tissue slice-glioma coculture model. Journal of Neurosurgery, 100(6), 1049–1059.
Edukulla, R., Woller, N., Mundt, B., Knocke, S., Gurlevik, E., Saborowski, M., Malek, N., Manns, M. P., Wirth, T., Kuhnel, F., & Kubicka, S. (2009). Antitumoral immune response by recruitment and expansion of dendritic cells in tumors infected with telomerase-dependent oncolytic viruses. Cancer Research, 69(4), 1448–1458.
Elankumaran, S., Chavan, V., Qiao, D., Shobana, R., Moorkanat, G., Biswas, M., & Samal, S. K. (2010). Type I interferon-sensitive recombinant newcastle disease virus for oncolytic virotherapy. Journal of Virology, 84(8), 3835–3844.
Enders, J. F., Weller, T. H., & Robbins, F. C. (1949). Cultivation of the lansing strain of poliomyelitis virus in cultures of various human embryonic tissues. Science, 109(2822), 85–87.
Engeland, C. E., Grossardt, C., Veinalde, R., Bossow, S., Lutz, D., Kaufmann, J. K., Shevchenko, I., Umansky, V., Nettelbeck, D. M., Weichert, W., Jager, D., von Kalle, C., & Ungerechts, G. (2014). CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy. Molecular Therapy: The Journal of the American Society of Gene Therapy, 22(11), 1949–1959.
Errington, F., Steele, L., Prestwich, R., Harrington, K. J., Pandha, H. S., Vidal, L., de Bono, J., Selby, P., Coffey, M., Vile, R., & Melcher, A. (2008). Reovirus activates human dendritic cells to promote innate antitumor immunity. Journal of Immunology, 180(9), 6018–6026.
Escobar-Zarate, D., Liu, Y. P., Suksanpaisan, L., Russell, S. J., & Peng, K. W. (2013). Overcoming cancer cell resistance to VSV oncolysis with JAK1/2 inhibitors. Cancer Gene Therapy, 20(10), 582–589.
Eshun, F. K., Currier, M. A., Gillespie, R. A., Fitzpatrick, J. L., Baird, W. H., & Cripe, T. P. (2010). VEGF blockade decreases the tumor uptake of systemic oncolytic herpes virus but enhances therapeutic efficacy when given after virotherapy. Gene Therapy, 17(7), 922–929.
Fang, L., Cheng, Q., Bai, J., Qi, Y. D., Liu, J. J., Li, L. T., & Zheng, J. N. (2013). An oncolytic adenovirus expressing interleukin-24 enhances antitumor activities in combination with paclitaxel in breast cancer cells. Molecular Medicine Reports, 8(5), 1416–1424.
Figueroa, J. A., Reidy, A., Mirandola, L., Trotter, K., Suvorava, N., Figueroa, A., Konala, V., Aulakh, A., Littlefield, L., Grizzi, F., Rahman, R. L., Jenkins, M. R., Musgrove, B., Radhi, S., D’Cunha, N., D’Cunha, L. N., Hermonat, P. L., Cobos, E., & Chiriva-Internati, M. (2015). Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy. International Reviews of Immunology, 34(2), 154–187.
Forbes, N. E., Abdelbary, H., Lupien, M., Bell, J. C., & Diallo, J. S. (2013). Exploiting tumor epigenetics to improve oncolytic virotherapy. Frontiers in Genetics, 4, 184.
Freeman, A. I., Zakay-Rones, Z., Gomori, J. M., Linetsky, E., Rasooly, L., Greenbaum, E., Rozenman-Yair, S., Panet, A., Libson, E., Irving, C. S., Galun, E., & Siegal, T. (2006). Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Molecular Therapy: The Journal of the American Society of Gene Therapy, 13(1), 221–228.
Frentzen, A., Yu, Y. A., Chen, N., Zhang, Q., Weibel, S., Raab, V., & Szalay, A. A. (2009). Anti-VEGF single-chain antibody GLAF-1 encoded by oncolytic vaccinia virus significantly enhances antitumor therapy. Proceedings of the National Academy of Sciences of the United States of America, 106(31), 12915–12920.
Freytag, S. O., Barton, K. N., & Zhang, Y. (2013). Efficacy of oncolytic adenovirus expressing suicide genes and interleukin-12 in preclinical model of prostate cancer. Gene Therapy, 20(12), 1131–1139.
Fu, X., Rivera, A., Tao, L., & Zhang, X. (2012). Incorporation of the B18R gene of vaccinia virus into an oncolytic herpes simplex virus improves antitumor activity. Molecular Therapy: The Journal of the American Society of Gene Therapy, 20(10), 1871–1881.
Fu, X., Rivera, A., Tao, L., & Zhang, X. (2015). An HSV-2 based oncolytic virus can function as an attractant to guide migration of adoptively transferred T cells to tumor sites. Oncotarget, 6(2), 902–914.
Fueyo, J., Alemany, R., Gomez-Manzano, C., Fuller, G. N., Khan, A., Conrad, C. A., Liu, T. J., Jiang, H., Lemoine, M. G., Suzuki, K., Sawaya, R., Curiel, D. T., Yung, W. K., & Lang, F. F. (2003). Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. Journal of the National Cancer Institute, 95(9), 652–660.
Fukuhara, H., Ino, Y., Kuroda, T., Martuza, R. L., & Todo, T. (2005). Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system. Cancer Research, 65(23), 10663–10668.
Fulci, G., Dmitrieva, N., Gianni, D., Fontana, E. J., Pan, X., Lu, Y., Kaufman, C. S., Kaur, B., Lawler, S. E., Lee, R. J., Marsh, C. B., Brat, D. J., van Rooijen, N., Stemmer-Rachamimov, A. O., Hochberg, F. H., Weissleder, R., Martuza, R. L., & Chiocca, E. A. (2007). Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses. Cancer Research, 67(19), 9398–9406.
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012). Coordinated regulation of myeloid cells by tumours. Nature Reviews Immunology, 12(4), 253–268.
Galivo, F., Diaz, R. M., Thanarajasingam, U., Jevremovic, D., Wongthida, P., Thompson, J., Kottke, T., Barber, G. N., Melcher, A., & Vile, R. G. (2010). Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus. Human Gene Therapy, 21(4), 439–450.
Galluzzi, L., & Lugli, E. (2013). Cancer immunotherapy turns viral. Oncoimmunology, 2(4), e24802.
Ganesh, S., Gonzalez Edick, M., Idamakanti, N., Abramova, M., Vanroey, M., Robinson, M., Yun, C. O., & Jooss, K. (2007). Relaxin-expressing, fiber chimeric oncolytic adenovirus prolongs survival of tumor-bearing mice. Cancer Research, 67(9), 4399–4407.
Ganly, I., Kirn, D., Eckhardt, G., Rodriguez, G. I., Soutar, D. S., Otto, R., Robertson, A. G., Park, O., Gulley, M. L., Heise, C., Von Hoff, D. D., & Kaye, S. B. (2000). A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 6(3), 798–806.
Gao, Y., Whitaker-Dowling, P., Griffin, J. A., Barmada, M. A., & Bergman, I. (2009). Recombinant vesicular stomatitis virus targeted to Her2/neu combined with anti-CTLA4 antibody eliminates implanted mammary tumors. Cancer Gene Therapy, 16(1), 44–52.
Garber, K. (2006). China approves world’s first oncolytic virus therapy for cancer treatment. Journal of the National Cancer Institute, 98(5), 298–300.
Gaston, D. C., Odom, C. I., Li, L., Markert, J. M., Roth, J. C., Cassady, K. A., Whitley, R. J., & Parker, J. N. (2013). Production of bioactive soluble interleukin-15 in complex with interleukin-15 receptor alpha from a conditionally-replicating oncolytic HSV-1. PLoS ONE, 8(11), e81768.
Gauvrit, A., Brandler, S., Sapede-Peroz, C., Boisgerault, N., Tangy, F., & Gregoire, M. (2008). Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response. Cancer Research, 68(12), 4882–4892.
Georgiades, J., Zielinski, T., Cicholska, A., & Jordan, E. (1959). Research on the oncolytic effect of APC viruses in cancer of the cervix uteri; preliminary report. Biuletyn Instytutu Medycyny Morskiej w Gdańsku, 10, 49–57.
Gholami, S., Marano, A., Chen, N. G., Aguilar, R. J., Frentzen, A., Chen, C. H., Lou, E., Fujisawa, S., Eveno, C., Belin, L., Zanzonico, P., Szalay, A., & Fong, Y. (2014). A novel vaccinia virus with dual oncolytic and anti-angiogenic therapeutic effects against triple-negative breast cancer. Breast Cancer Research and Treatment, 148(3), 489–499.
Gil, M., Seshadri, M., Komorowski, M. P., Abrams, S. I., & Kozbor, D. (2013). Targeting CXCL12/CXCR4 signaling with oncolytic virotherapy disrupts tumor vasculature and inhibits breast cancer metastases. Proceedings of the National Academy of Sciences of the United States of America, 110(14), E1291–E1300.
Gil, M., Komorowski, M. P., Seshadri, M., Rokita, H., McGray, A. J., Opyrchal, M., Odunsi, K. O., & Kozbor, D. (2014). CXCL12/CXCR4 blockade by oncolytic virotherapy inhibits ovarian cancer growth by decreasing immunosuppression and targeting cancer-initiating cells. Journal of Immunology, 193(10), 5327–5337.
Goetz, C., Dobrikova, E., Shveygert, M., Dobrikov, M., & Gromeier, M. (2011). Oncolytic poliovirus against malignant glioma. Future Virology, 6(9), 1045–1058.
Gomes, E. M., Rodrigues, M. S., Phadke, A. P., Butcher, L. D., Starling, C., Chen, S., Chang, D., Hernandez-Alcoceba, R., Newman, J. T., Stone, M. J., & Tong, A. W. (2009). Antitumor activity of an oncolytic adenoviral-CD40 ligand (CD154) transgene construct in human breast cancer cells. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 15(4), 1317–1325.
Green, D. R., Ferguson, T., Zitvogel, L., & Kroemer, G. (2009). Immunogenic and tolerogenic cell death. Nature Reviews Immunology, 9(5), 353–363.
Gross, S. (1971). Measles and leukaemia. Lancet, 1(7695), 397–398.
Grossardt, C., Engeland, C. E., Bossow, S., Halama, N., Zaoui, K., Leber, M. F., Springfeld, C., Jaeger, D., von Kalle, C., & Ungerechts, G. (2013). Granulocyte-macrophage colony-stimulating factor-armed oncolytic measles virus is an effective therapeutic cancer vaccine. Human Gene Therapy, 24(7), 644–654.
Grote, D., Russell, S. J., Cornu, T. I., Cattaneo, R., Vile, R., Poland, G. A., & Fielding, A. K. (2001). Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. Blood, 97(12), 3746–3754.
Grote, D., Cattaneo, R., & Fielding, A. K. (2003). Neutrophils contribute to the measles virus-induced antitumor effect: Enhancement by granulocyte macrophage colony-stimulating factor expression. Cancer Research, 63(19), 6463–6468.
Guedan, S., Grases, D., Rojas, J. J., Gros, A., Vilardell, F., Vile, R., Mercade, E., Cascallo, M., & Alemany, R. (2012). GALV expression enhances the therapeutic efficacy of an oncolytic adenovirus by inducing cell fusion and enhancing virus distribution. Gene Therapy, 19(11), 1048–1057.
Hammon, W. M., Yohn, D. S., Casto, B. C., & Atchison, R. W. (1963). Oncolytic potentials Of nonhuman viruses for human cancer. I. Effects of twenty-four viruses on human cancer cell lines. Journal of the National Cancer Institute, 31, 329–345.
Han, Z. Q., Assenberg, M., Liu, B. L., Wang, Y. B., Simpson, G., Thomas, S., & Coffin, R. S. (2007). Development of a second-generation oncolytic Herpes simplex virus expressing TNFalpha for cancer therapy. The Journal of Gene Medicine, 9(2), 99–106.
Harada, J. N., & Berk, A. J. (1999). p53-Independent and -dependent requirements for E1B-55K in adenovirus type 5 replication. Journal of Virology, 73(7), 5333–5344.
Heine, A., Held, S. A., Daecke, S. N., Wallner, S., Yajnanarayana, S. P., Kurts, C., Wolf, D., & Brossart, P. (2013). The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood, 122(7), 1192–1202.
Heise, C., Sampson-Johannes, A., Williams, A., McCormick, F., Von Hoff, D. D., & Kirn, D. H. (1997). ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nature Medicine, 3(6), 639–645.
Heo, J., Reid, T., Ruo, L., Breitbach, C. J., Rose, S., Bloomston, M., Cho, M., Lim, H. Y., Chung, H. C., Kim, C. W., Burke, J., Lencioni, R., Hickman, T., Moon, A., Lee, Y. S., Kim, M. K., Daneshmand, M., Dubois, K., Longpre, L., Ngo, M., Rooney, C., Bell, J. C., Rhee, B. G., Patt, R., Hwang, T. H., & Kirn, D. H. (2013). Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nature Medicine, 19(3), 329–336.
Hoster, H. A., Zanes, R. P., Jr., & Von Haam, E. (1949). Studies in Hodgkin’s syndrome; the association of viral hepatitis and Hodgkin’s disease; a preliminary report. Cancer Research, 9(8), 473–480.
Hou, W., Chen, H., Rojas, J., Sampath, P., & Thorne, S. H. (2014). Oncolytic vaccinia virus demonstrates antiangiogenic effects mediated by targeting of VEGF. International Journal of Cancer Journal International du Cancer, 135(5), 1238–1246.
Hu, J. C., Coffin, R. S., Davis, C. J., Graham, N. J., Groves, N., Guest, P. J., Harrington, K. J., James, N. D., Love, C. A., McNeish, I., Medley, L. C., Michael, A., Nutting, C. M., Pandha, H. S., Shorrock, C. A., Simpson, J., Steiner, J., Steven, N. M., Wright, D., & Coombes, R. C. (2006). A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 12(22), 6737–6747.
Hu, Z. B., Wu, C. T., Wang, H., Zhang, Q. W., Wang, L., Wang, R. L., Lu, Z. Z., & Wang, L. S. (2008). A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes. Cancer Gene Therapy, 15(3), 173–182.
Hu, Z., Gupta, J., Zhang, Z., Gerseny, H., Berg, A., Chen, Y. J., Zhang, Z., Du, H., Brendler, C. B., Xiao, X., Pienta, K. J., Guise, T., Lee, C., Stern, P. H., Stock, S., & Seth, P. (2012). Systemic delivery of oncolytic adenoviruses targeting transforming growth factor-beta inhibits established bone metastasis in a prostate cancer mouse model. Human Gene Therapy, 23(8), 871–882.
Huang, P. I., Chang, J. F., Kirn, D. H., & Liu, T. C. (2009). Targeted genetic and viral therapy for advanced head and neck cancers. Drug Discovery Today, 14(11–12), 570–578.
Huang, J. H., Zhang, S. N., Choi, K. J., Choi, I. K., Kim, J. H., Lee, M. G., Kim, H., & Yun, C. O. (2010). Therapeutic and tumor-specific immunity induced by combination of dendritic cells and oncolytic adenovirus expressing IL-12 and 4-1BBL. Molecular Therapy: The Journal of the American Society of Gene Therapy, 18(2), 264–274.
Huang, T. T., Hlavaty, J., Ostertag, D., Espinoza, F. L., Martin, B., Petznek, H., Rodriguez-Aguirre, M., Ibanez, C. E., Kasahara, N., Gunzburg, W., Gruber, H. E., Pertschuk, D., Jolly, D. J., & Robbins, J. M. (2013). Toca 511 gene transfer and 5-fluorocytosine in combination with temozolomide demonstrates synergistic therapeutic efficacy in a temozolomide-sensitive glioblastoma model. Cancer Gene Therapy, 20(10), 544–551.
Ino, Y., Saeki, Y., Fukuhara, H., & Todo, T. (2006). Triple combination of oncolytic herpes simplex virus-1 vectors armed with interleukin-12, interleukin-18, or soluble B7-1 results in enhanced antitumor efficacy. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 12(2), 643–652.
Inoue, H., & Tani, K. (2014). Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments. Cell Death and Differentiation, 21(1), 39–49.
Jenks, N., Myers, R., Greiner, S. M., Thompson, J., Mader, E. K., Greenslade, A., Griesmann, G. E., Federspiel, M. J., Rakela, J., Borad, M. J., Vile, R. G., Barber, G. N., Meier, T. R., Blanco, M. C., Carlson, S. K., Russell, S. J., & Peng, K. W. (2010). Safety studies on intrahepatic or intratumoral injection of oncolytic vesicular stomatitis virus expressing interferon-beta in rodents and nonhuman primates. Human Gene Therapy, 21(4), 451–462.
Jin, J., Liu, H., Yang, C., Li, G., Liu, X., Qian, Q., & Qian, W. (2009). Effective gene-viral therapy of leukemia by a new fiber chimeric oncolytic adenovirus expressing TRAIL: In vitro and in vivo evaluation. Molecular Cancer Therapeutics, 8(5), 1387–1397.
Joffre, O., Nolte, M. A., Sporri, R., & Reis e Sousa, C. (2009). Inflammatory signals in dendritic cell activation and the induction of adaptive immunity. Immunological Reviews, 227(1), 234–247.
John, L. B., Howland, L. J., Flynn, J. K., West, A. C., Devaud, C., Duong, C. P., Stewart, T. J., Westwood, J. A., Guo, Z. S., Bartlett, D. L., Smyth, M. J., Kershaw, M. H., & Darcy, P. K. (2012). Oncolytic virus and anti-4-1BB combination therapy elicits strong antitumor immunity against established cancer. Cancer Research, 72(7), 1651–1660.
Kanai, R., Wakimoto, H., Martuza, R. L., & Rabkin, S. D. (2011). A novel oncolytic herpes simplex virus that synergizes with phosphoinositide 3-kinase/Akt pathway inhibitors to target glioblastoma stem cells. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 17(11), 3686–3696.
Kanerva, A., Nokisalmi, P., Diaconu, I., Koski, A., Cerullo, V., Liikanen, I., Tahtinen, S., Oksanen, M., Heiskanen, R., Pesonen, S., Joensuu, T., Alanko, T., Partanen, K., Laasonen, L., Kairemo, K., Pesonen, S., Kangasniemi, L., & Hemminki, A. (2013). Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 19(10), 2734–2744.
Kaufman, H. L., & Bines, S. D. (2010). OPTIM trial: A Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma. Future Oncology, 6(6), 941–949.
Kaufman, H. L., Kim, D. W., DeRaffele, G., Mitcham, J., Coffin, R. S., & Kim-Schulze, S. (2010). Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Annals of Surgical Oncology, 17(3), 718–730.
Kelly, E. J., & Russell, S. J. (2009). MicroRNAs and the regulation of vector tropism. Molecular Therapy: The Journal of the American Society of Gene Therapy, 17(3), 409–416.
Kelly, E. J., Hadac, E. M., Greiner, S., & Russell, S. J. (2008). Engineering microRNA responsiveness to decrease virus pathogenicity. Nature Medicine, 14(11), 1278–1283.
Kelly, K., Nawrocki, S., Mita, A., Coffey, M., Giles, F. J., & Mita, M. (2009). Reovirus-based therapy for cancer. Expert Opinion on Biological Therapy, 9(7), 817–830.
Kenney, S., & Pagano, J. S. (1994). Viruses as oncolytic agents: A new age for “therapeutic” viruses? Journal of the National Cancer Institute, 86(16), 1185–1186.
Khuri, F. R., Nemunaitis, J., Ganly, I., Arseneau, J., Tannock, I. F., Romel, L., Gore, M., Ironside, J., MacDougall, R. H., Heise, C., Randlev, B., Gillenwater, A. M., Bruso, P., Kaye, S. B., Hong, W. K., & Kirn, D. H. (2000). A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nature Medicine, 6(8), 879–885.
Kim, H. S., Kim-Schulze, S., Kim, D. W., & Kaufman, H. L. (2009). Host lymphodepletion enhances the therapeutic activity of an oncolytic vaccinia virus expressing 4-1BB ligand. Cancer Research, 69(21), 8516–8525.
Kim, W., Seong, J., Oh, H. J., Koom, W. S., Choi, K. J., & Yun, C. O. (2011). A novel combination treatment of armed oncolytic adenovirus expressing IL-12 and GM-CSF with radiotherapy in murine hepatocarcinoma. Journal of Radiation Research, 52(5), 646–654.
Kirn, D. H., Wang, Y., Le Boeuf, F., Bell, J., & Thorne, S. H. (2007). Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus. PLoS Medicine, 4(12), e353.
Koski, A., Kangasniemi, L., Escutenaire, S., Pesonen, S., Cerullo, V., Diaconu, I., Nokisalmi, P., Raki, M., Rajecki, M., Guse, K., Ranki, T., Oksanen, M., Holm, S. L., Haavisto, E., Karioja-Kallio, A., Laasonen, L., Partanen, K., Ugolini, M., Helminen, A., Karli, E., Hannuksela, P., Pesonen, S., Joensuu, T., Kanerva, A., & Hemminki, A. (2010). Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF. Molecular Therapy: The Journal of the American Society of Gene Therapy, 18(10), 1874–1884.
Kottke, T., Galivo, F., Wongthida, P., Diaz, R. M., Thompson, J., Jevremovic, D., Barber, G. N., Hall, G., Chester, J., Selby, P., Harrington, K., Melcher, A., & Vile, R. G. (2008). Treg depletion-enhanced IL-2 treatment facilitates therapy of established tumors using systemically delivered oncolytic virus. Molecular Therapy: The Journal of the American Society of Gene Therapy, 16(7), 1217–1226.
Kottke, T., Thompson, J., Diaz, R. M., Pulido, J., Willmon, C., Coffey, M., Selby, P., Melcher, A., Harrington, K., & Vile, R. G. (2009). Improved systemic delivery of oncolytic reovirus to established tumors using preconditioning with cyclophosphamide-mediated Treg modulation and interleukin-2. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 15(2), 561–569.
Krysko, D. V., Garg, A. D., Kaczmarek, A., Krysko, O., Agostinis, P., & Vandenabeele, P. (2012). Immunogenic cell death and DAMPs in cancer therapy. Nature Reviews Cancer, 12(12), 860–875.
Kueberuwa, G., Cawood, R., & Seymour, L. W. (2010). Blood compatibility of enveloped viruses. Current Opinion in Molecular Therapeutics, 12(4), 412–420.
Kuhn, I., Harden, P., Bauzon, M., Chartier, C., Nye, J., Thorne, S., Reid, T., Ni, S., Lieber, A., Fisher, K., Seymour, L., Rubanyi, G. M., Harkins, R. N., & Hermiston, T. W. (2008). Directed evolution generates a novel oncolytic virus for the treatment of colon cancer. PLoS ONE, 3(6), e2409.
Kumar, S., Gao, L., Yeagy, B., & Reid, T. (2008). Virus combinations and chemotherapy for the treatment of human cancers. Current Opinion in Molecular Therapeutics, 10(4), 371–379.
Kuriyama, N., Kuriyama, H., Julin, C. M., Lamborn, K., & Israel, M. A. (2000). Pretreatment with protease is a useful experimental strategy for enhancing adenovirus-mediated cancer gene therapy. Human Gene Therapy, 11(16), 2219–2230.
Lapteva, N., Aldrich, M., Weksberg, D., Rollins, L., Goltsova, T., Chen, S. Y., & Huang, X. F. (2009). Targeting the intratumoral dendritic cells by the oncolytic adenoviral vaccine expressing RANTES elicits potent antitumor immunity. Journal of Immunotherapy, 32(2), 145–156.
LaRocca, C. J., Han, J., Gavrikova, T., Armstrong, L., Oliveira, A. R., Shanley, R., Vickers, S. M., Yamamoto, M., & Davydova, J. (2015). Oncolytic adenovirus expressing interferon alpha in a syngeneic Syrian hamster model for the treatment of pancreatic cancer. Surgery, 157(5), 888–898.
Lavilla-Alonso, S., Bauer, M. M., Abo-Ramadan, U., Ristimaki, A., Halavaara, J., Desmond, R. A., Wang, D., Escutenaire, S., Ahtiainen, L., Saksela, K., Tatlisumak, T., Hemminki, A., & Pesonen, S. (2012). Macrophage metalloelastase (MME) as adjuvant for intra-tumoral injection of oncolytic adenovirus and its influence on metastases development. Cancer Gene Therapy, 19(2), 126–134.
Le Boeuf, F., Batenchuk, C., Vaha-Koskela, M., Breton, S., Roy, D., Lemay, C., Cox, J., Abdelbary, H., Falls, T., Waghray, G., Atkins, H., Stojdl, D., Diallo, J. S., Kaern, M., & Bell, J. C. (2013). Model-based rational design of an oncolytic virus with improved therapeutic potential. Nature Communications, 4, 1974.
Lee, Y. S., Kim, J. H., Choi, K. J., Choi, I. K., Kim, H., Cho, S., Cho, B. C., & Yun, C. O. (2006). Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 12(19), 5859–5868.
Lei, N., Shen, F. B., Chang, J. H., Wang, L., Li, H., Yang, C., Li, J., & Yu, D. C. (2009). An oncolytic adenovirus expressing granulocyte macrophage colony-stimulating factor shows improved specificity and efficacy for treating human solid tumors. Cancer Gene Therapy, 16(1), 33–43.
Lerner, B. H. (2004). Sins of omission – cancer research without informed consent. The New England Journal of Medicine, 351(7), 628–630.
Leveille, S., Goulet, M. L., Lichty, B. D., & Hiscott, J. (2011). Vesicular stomatitis virus oncolytic treatment interferes with tumor-associated dendritic cell functions and abrogates tumor antigen presentation. Journal of Virology, 85(23), 12160–12169.
Li, Y., Wang, L. X., Yang, G., Hao, F., Urba, W. J., & Hu, H. M. (2008). Efficient cross-presentation depends on autophagy in tumor cells. Cancer Research, 68(17), 6889–6895.
Li, J. L., Liu, H. L., Zhang, X. R., Xu, J. P., Hu, W. K., Liang, M., Chen, S. Y., Hu, F., & Chu, D. T. (2009). A phase I trial of intratumoral administration of recombinant oncolytic adenovirus overexpressing HSP70 in advanced solid tumor patients. Gene Therapy, 16(3), 376–382.
Li, H., Peng, K. W., Dingli, D., Kratzke, R. A., & Russell, S. J. (2010). Oncolytic measles viruses encoding interferon beta and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy. Cancer Gene Therapy, 17(8), 550–558.
Li, J., O’Malley, M., Urban, J., Sampath, P., Guo, Z. S., Kalinski, P., Thorne, S. H., & Bartlett, D. L. (2011). Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer. Molecular Therapy: The Journal of the American Society of Gene Therapy, 19(4), 650–657.
Li, J., O’Malley, M., Sampath, P., Kalinski, P., Bartlett, D. L., & Thorne, S. H. (2012). Expression of CCL19 from oncolytic vaccinia enhances immunotherapeutic potential while maintaining oncolytic activity. Neoplasia, 14(12), 1115–1121.
Li, J., Liu, H., Li, L., Wu, H., Wang, C., Yan, Z., Wang, Y., Su, C., Jin, H., Zhou, F., Wu, M., & Qian, Q. (2013). The combination of an oxygen-dependent degradation domain-regulated adenovirus expressing the chemokine RANTES/CCL5 and NK-92 cells exerts enhanced antitumor activity in hepatocellular carcinoma. Oncology Reports, 29(3), 895–902.
Lichty, B. D., Breitbach, C. J., Stojdl, D. F., & Bell, J. C. (2014). Going viral with cancer immunotherapy. Nature Reviews Cancer, 14(8), 559–567.
Lindenmann, J., & Klein, P. A. (1967). Viral oncolysis: Increased immunogenicity of host cell antigen associated with influenza virus. The Journal of Experimental Medicine, 126(1), 93–108.
Liu, B. L., Robinson, M., Han, Z. Q., Branston, R. H., English, C., Reay, P., McGrath, Y., Thomas, S. K., Thornton, M., Bullock, P., Love, C. A., & Coffin, R. S. (2003). ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Therapy, 10(4), 292–303.
Liu, X. Y., Qiu, S. B., Zou, W. G., Pei, Z. F., Gu, J. F., Luo, C. X., Ruan, H. M., Chen, Y., Qi, Y. P., & Qian, C. (2005). Effective gene-virotherapy for complete eradication of tumor mediated by the combination of hTRAIL (TNFSF10) and plasminogen k5. Molecular Therapy: The Journal of the American Society of Gene Therapy, 11(4), 531–541.
Liu, T. C., Galanis, E., & Kirn, D. (2007). Clinical trial results with oncolytic virotherapy: A century of promise, a decade of progress. Nature Clinical Practice Oncology, 4(2), 101–117.
Liu, J., Wennier, S., Reinhard, M., Roy, E., MacNeill, A., & McFadden, G. (2009). Myxoma virus expressing interleukin-15 fails to cause lethal myxomatosis in European rabbits. Journal of Virology, 83(11), 5933–5938.
Liu, X., Cao, X., Wei, R., Cai, Y., Li, H., Gui, J., Zhong, D., Liu, X. Y., & Huang, K. (2012). Gene-viro-therapy targeting liver cancer by a dual-regulated oncolytic adenoviral vector harboring IL-24 and TRAIL. Cancer Gene Therapy, 19(1), 49–57.
Liu, Y. P., Suksanpaisan, L., Steele, M. B., Russell, S. J., & Peng, K. W. (2013). Induction of antiviral genes by the tumor microenvironment confers resistance to virotherapy. Scientific Reports, 3, 2375.
Lu, P., Weaver, V. M., & Werb, Z. (2012). The extracellular matrix: A dynamic niche in cancer progression. The Journal of Cell Biology, 196(4), 395–406.
MacKie, R. M., Stewart, B., & Brown, S. M. (2001). Intralesional injection of herpes simplex virus 1716 in metastatic melanoma. Lancet, 357(9255), 525–526.
Magge, D., Guo, Z. S., O’Malley, M. E., Francis, L., Ravindranathan, R., & Bartlett, D. L. (2013). Inhibitors of C5 complement enhance vaccinia virus oncolysis. Cancer Gene Therapy, 20(6), 342–350.
Mahoney, D. J., Lefebvre, C., Allan, K., Brun, J., Sanaei, C. A., Baird, S., Pearce, N., Gronberg, S., Wilson, B., Prakesh, M., Aman, A., Isaac, M., Mamai, A., Uehling, D., Al-Awar, R., Falls, T., Alain, T., & Stojdl, D. F. (2011). Virus-tumor interactome screen reveals ER stress response can reprogram resistant cancers for oncolytic virus-triggered caspase-2 cell death. Cancer Cell, 20(4), 443–456.
Marabelle, A., Kohrt, H., Sagiv-Barfi, I., Ajami, B., Axtell, R. C., Zhou, G., Rajapaksa, R., Green, M. R., Torchia, J., Brody, J., Luong, R., Rosenblum, M. D., Steinman, L., Levitsky, H. I., Tse, V., & Levy, R. (2013). Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. The Journal of Clinical Investigation, 123(6), 2447–2463.
Markert, J. M., Malick, A., Coen, D. M., & Martuza, R. L. (1993). Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir. Neurosurgery, 32(4), 597–603.
Martuza, R. L., Malick, A., Markert, J. M., Ruffner, K. L., & Coen, D. M. (1991). Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science, 252(5007), 854–856.
Mastrangelo, M. J., Maguire, H. C., Jr., Eisenlohr, L. C., Laughlin, C. E., Monken, C. E., McCue, P. A., Kovatich, A. J., & Lattime, E. C. (1999). Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Therapy, 6(5), 409–422.
McCormick, F. (2000). ONYX-015 selectivity and the p14ARF pathway. Oncogene, 19(56), 6670–6672.
McCormick, F. (2003). Cancer-specific viruses and the development of ONYX-015. Cancer Biology & Therapy, 2(4 Suppl 1), S157–S160.
McKee, T. D., Grandi, P., Mok, W., Alexandrakis, G., Insin, N., Zimmer, J. P., Bawendi, M. G., Boucher, Y., Breakefield, X. O., & Jain, R. K. (2006). Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. Cancer Research, 66(5), 2509–2513.
Melcher, A., Todryk, S., Hardwick, N., Ford, M., Jacobson, M., & Vile, R. G. (1998). Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nature Medicine, 4(5), 581–587.
Meng, X., Nakamura, T., Okazaki, T., Inoue, H., Takahashi, A., Miyamoto, S., Sakaguchi, G., Eto, M., Naito, S., Takeda, M., Yanagi, Y., & Tani, K. (2010). Enhanced antitumor effects of an engineered measles virus Edmonston strain expressing the wild-type N, P, L genes on human renal cell carcinoma. Molecular Therapy: The Journal of the American Society of Gene Therapy, 18(3), 544–551.
Miller, J. M., Bidula, S. M., Jensen, T. M., & Reiss, C. S. (2010). Vesicular stomatitis virus modified with single chain IL-23 exhibits oncolytic activity against tumor cells in vitro and in vivo. International Journal of Interferon Cytokine and Mediator Research: IJIM, 2010(2), 63–72.
Minchinton, A. I., & Tannock, I. F. (2006). Drug penetration in solid tumours. Nature Reviews Cancer, 6(8), 583–592.
Moerdyk-Schauwecker, M., Shah, N. R., Murphy, A. M., Hastie, E., Mukherjee, P., & Grdzelishvili, V. Z. (2013). Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: Role of type I interferon signaling. Virology, 436(1), 221–234.
Molomut, N., & Padnos, M. (1965). Inhibition of transplantable and spontaneous murine tumours by the M-P virus. Nature, 208(5014), 948–950.
Moore, A. E. (1949). The destructive effect of the virus of Russian Far East encephalitis on the transplantable mouse sarcoma 180. Cancer, 2(3), 525–534.
Moore, A. E. (1951). Inhibition of growth of five transplantable mouse tumors by the virus of Russian Far East encephalitis. Cancer, 4(2), 375–382.
Moore, A. E. (1952). Viruses with oncolytic properties and their adaptation to tumors. Annals of the New York Academy of Sciences, 54(6), 945–952.
Mori, I., Liu, B., Goshima, F., Ito, H., Koide, N., Yoshida, T., Yokochi, T., Kimura, Y., & Nishiyama, Y. (2005). HF10, an attenuated herpes simplex virus (HSV) type 1 clone, lacks neuroinvasiveness and protects mice against lethal challenge with HSV types 1 and 2. Microbes and Infection/Institut Pasteur, 7(15), 1492–1500.
Msaouel, P., Iankov, I. D., Dispenzieri, A., & Galanis, E. (2012). Attenuated oncolytic measles virus strains as cancer therapeutics. Current Pharmaceutical Biotechnology, 13(9), 1732–1741.
Muhlbauer, M., Fleck, M., Schutz, C., Weiss, T., Froh, M., Blank, C., Scholmerich, J., & Hellerbrand, C. (2006). PD-L1 is induced in hepatocytes by viral infection and by interferon-alpha and -gamma and mediates T cell apoptosis. Journal of Hepatology, 45(4), 520–528.
Muller, U., Steinhoff, U., Reis, L. F., Hemmi, S., Pavlovic, J., Zinkernagel, R. M., & Aguet, M. (1994). Functional role of type I and type II interferons in antiviral defense. Science, 264(5167), 1918–1921.
Murray, D. R., Cassel, W. A., Torbin, A. H., Olkowski, Z. L., & Moore, M. E. (1977). Viral oncolysate in the management of malignant melanoma. II. Clinical studies. Cancer, 40(2), 680–686.
Muthana, M., Rodrigues, S., Chen, Y. Y., Welford, A., Hughes, R., Tazzyman, S., Essand, M., Morrow, F., & Lewis, C. E. (2013). Macrophage delivery of an oncolytic virus abolishes tumor regrowth and metastasis after chemotherapy or irradiation. Cancer Research, 73(2), 490–495.
Nagano, S., Perentes, J. Y., Jain, R. K., & Boucher, Y. (2008). Cancer cell death enhances the penetration and efficacy of oncolytic herpes simplex virus in tumors. Cancer Research, 68(10), 3795–3802.
Naik, S., Nace, R., Barber, G. N., & Russell, S. J. (2012). Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-beta. Cancer Gene Therapy, 19(7), 443–450.
Nakashima, H., Kaur, B., & Chiocca, E. A. (2010). Directing systemic oncolytic viral delivery to tumors via carrier cells. Cytokine & Growth Factor Reviews, 21(2–3), 119–126.
Nemunaitis, J., Khuri, F., Ganly, I., Arseneau, J., Posner, M., Vokes, E., Kuhn, J., McCarty, T., Landers, S., Blackburn, A., Romel, L., Randlev, B., Kaye, S., & Kirn, D. (2001). Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 19(2), 289–298.
Nguyen, A., Ho, L., & Wan, Y. (2014). Chemotherapy and oncolytic virotherapy: Advanced tactics in the war against cancer. Frontiers in Oncology, 4, 145.
O’Shea, C. C., Johnson, L., Bagus, B., Choi, S., Nicholas, C., Shen, A., Boyle, L., Pandey, K., Soria, C., Kunich, J., Shen, Y., Habets, G., Ginzinger, D., & McCormick, F. (2004). Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell, 6(6), 611–623.
O’Shea, C. C., Soria, C., Bagus, B., & McCormick, F. (2005). Heat shock phenocopies E1B-55K late functions and selectively sensitizes refractory tumor cells to ONYX-015 oncolytic viral therapy. Cancer Cell, 8(1), 61–74.
Obuchi, M., Fernandez, M., & Barber, G. N. (2003). Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity. Journal of Virology, 77(16), 8843–8856.
Ottolino-Perry, K., Diallo, J. S., Lichty, B. D., Bell, J. C., & McCart, J. A. (2010). Intelligent design: Combination therapy with oncolytic viruses. Molecular Therapy: The Journal of the American Society of Gene Therapy, 18(2), 251–263.
Paglino, J. C., & van den Pol, A. N. (2011). Vesicular stomatitis virus has extensive oncolytic activity against human sarcomas: Rare resistance is overcome by blocking interferon pathways. Journal of Virology, 85(18), 9346–9358.
Park, B. H., Hwang, T., Liu, T. C., Sze, D. Y., Kim, J. S., Kwon, H. C., Oh, S. Y., Han, S. Y., Yoon, J. H., Hong, S. H., Moon, A., Speth, K., Park, C., Ahn, Y. J., Daneshmand, M., Rhee, B. G., Pinedo, H. M., Bell, J. C., & Kirn, D. H. (2008). Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: A phase I trial. The Lancet Oncology, 9(6), 533–542.
Parker, J. N., Gillespie, G. Y., Love, C. E., Randall, S., Whitley, R. J., & Markert, J. M. (2000). Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. Proceedings of the National Academy of Sciences of the United States of America, 97(5), 2208–2213.
Parker, J. N., Meleth, S., Hughes, K. B., Gillespie, G. Y., Whitley, R. J., & Markert, J. M. (2005). Enhanced inhibition of syngeneic murine tumors by combinatorial therapy with genetically engineered HSV-1 expressing CCL2 and IL-12. Cancer Gene Therapy, 12(4), 359–368.
Parrish, C. R., & Kawaoka, Y. (2005). The origins of new pandemic viruses: The acquisition of new host ranges by canine parvovirus and influenza A viruses. Annual Review of Microbiology, 59, 553–586.
Parviainen, S., Ahonen, M., Diaconu, I., Hirvinen, M., Karttunen, A., Vaha-Koskela, M., Hemminki, A., & Cerullo, V. (2014). CD40 ligand and tdTomato-armed vaccinia virus for induction of antitumor immune response and tumor imaging. Gene Therapy, 21(2), 195–204.
Pasquinucci, G. (1971). Possible effect of measles on leukaemia. Lancet, 1(7690), 136.
Passer, B. J., Cheema, T., Zhou, B., Wakimoto, H., Zaupa, C., Razmjoo, M., Sarte, J., Wu, S., Wu, C. L., Noah, J. W., Li, Q., Buolamwini, J. K., Yen, Y., Rabkin, S. D., & Martuza, R. L. (2010). Identification of the ENT1 antagonists dipyridamole and dilazep as amplifiers of oncolytic herpes simplex virus-1 replication. Cancer Research, 70(10), 3890–3895.
Passer, B. J., Cheema, T., Wu, S., Wu, C. L., Rabkin, S. D., & Martuza, R. L. (2013). Combination of vinblastine and oncolytic herpes simplex virus vector expressing IL-12 therapy increases antitumor and antiangiogenic effects in prostate cancer models. Cancer Gene Therapy, 20(1), 17–24.
Patel, M. R., & Kratzke, R. A. (2013). Oncolytic virus therapy for cancer: The first wave of translational clinical trials. Translational Research: The Journal of Laboratory and Clinical Medicine, 161(4), 355–364.
Pearson, S., Jia, H., & Kandachi, K. (2004). China approves first gene therapy. Nature Biotechnology, 22(1), 3–4.
Pelner, L., Fowler, G. A., & Nauts, H. C. (1958). Effects of concurrent infections and their toxins on the course of leukemia. Acta Medica Scandinavica. Supplementum, 338, 1–47.
Perez, O. D., Logg, C. R., Hiraoka, K., Diago, O., Burnett, R., Inagaki, A., Jolson, D., Amundson, K., Buckley, T., Lohse, D., Lin, A., Burrascano, C., Ibanez, C., Kasahara, N., Gruber, H. E., & Jolly, D. J. (2012). Design and selection of Toca 511 for clinical use: Modified retroviral replicating vector with improved stability and gene expression. Molecular Therapy: The Journal of the American Society of Gene Therapy, 20(9), 1689–1698.
Pesonen, S., Diaconu, I., Kangasniemi, L., Ranki, T., Kanerva, A., Pesonen, S. K., Gerdemann, U., Leen, A. M., Kairemo, K., Oksanen, M., Haavisto, E., Holm, S. L., Karioja-Kallio, A., Kauppinen, S., Partanen, K. P., Laasonen, L., Joensuu, T., Alanko, T., Cerullo, V., & Hemminki, A. (2012). Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: Assessment of safety and immunologic responses in patients. Cancer Research, 72(7), 1621–1631.
Pol, J., Bloy, N., Obrist, F., Eggermont, A., Galon, J., Cremer, I., Erbs, P., Limacher, J. M., Preville, X., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014). Trial watch: Oncolytic viruses for cancer therapy. Oncoimmunology, 3, e28694.
Pond, A. R., & Manuelidis, E. E. (1964). Oncolytic effect of poliomyelitis virus on human epidermoid carcinoma (Hela Tumor) heterologously transplanted to Guinea Pigs. The American Journal of Pathology, 45, 233–249.
Post, D. E., Sandberg, E. M., Kyle, M. M., Devi, N. S., Brat, D. J., Xu, Z., Tighiouart, M., & Van Meir, E. G. (2007). Targeted cancer gene therapy using a hypoxia inducible factor dependent oncolytic adenovirus armed with interleukin-4. Cancer Research, 67(14), 6872–6881.
Power, A. T., & Bell, J. C. (2008). Taming the Trojan horse: Optimizing dynamic carrier cell/oncolytic virus systems for cancer biotherapy. Gene Therapy, 15(10), 772–779.
Prestwich, R. J., Ilett, E. J., Errington, F., Diaz, R. M., Steele, L. P., Kottke, T., Thompson, J., Galivo, F., Harrington, K. J., Pandha, H. S., Selby, P. J., Vile, R. G., & Melcher, A. A. (2009). Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 15(13), 4374–4381.
Racaniello, V. R., & Baltimore, D. (1981a). Cloned poliovirus complementary DNA is infectious in mammalian cells. Science, 214(4523), 916–919.
Racaniello, V. R., & Baltimore, D. (1981b). Molecular cloning of poliovirus cDNA and determination of the complete nucleotide sequence of the viral genome. Proceedings of the National Academy of Sciences of the United States of America, 78(8), 4887–4891.
Radestock, Y., Hoang-Vu, C., & Hombach-Klonisch, S. (2008). Relaxin reduces xenograft tumour growth of human MDA-MB-231 breast cancer cells. Breast Cancer Research: BCR, 10(4), R71.
Ramesh, N., Ge, Y., Ennist, D. L., Zhu, M., Mina, M., Ganesh, S., Reddy, P. S., & Yu, D. C. (2006). CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor – Armed oncolytic adenovirus for the treatment of bladder cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 12(1), 305–313.
Randazzo, B. P., Kucharczuk, J. C., Litzky, L. A., Kaiser, L. R., Brown, S. M., MacLean, A., Albelda, S. M., & Fraser, N. W. (1996). Herpes simplex 1716 – An ICP 34.5 mutant – Is severely replication restricted in human skin xenografts in vivo. Virology, 223(2), 392–395.
Reddy, P. S., Burroughs, K. D., Hales, L. M., Ganesh, S., Jones, B. H., Idamakanti, N., Hay, C., Li, S. S., Skele, K. L., Vasko, A. J., Yang, J., Watkins, D. N., Rudin, C. M., & Hallenbeck, P. L. (2007). Seneca Valley virus, a systemically deliverable oncolytic picornavirus, and the treatment of neuroendocrine cancers. Journal of the National Cancer Institute, 99(21), 1623–1633.
Reichard, K. W., Lorence, R. M., Cascino, C. J., Peeples, M. E., Walter, R. J., Fernando, M. B., Reyes, H. M., & Greager, J. A. (1992). Newcastle disease virus selectively kills human tumor cells. The Journal of Surgical Research, 52(5), 448–453.
Restifo, N. P., Dudley, M. E., & Rosenberg, S. A. (2012). Adoptive immunotherapy for cancer: Harnessing the T cell response. Nature Reviews Immunology, 12(4), 269–281.
Rock, K. L., Lai, J. J., & Kono, H. (2011). Innate and adaptive immune responses to cell death. Immunological Reviews, 243(1), 191–205.
Roland, C. L., Lynn, K. D., Toombs, J. E., Dineen, S. P., Udugamasooriya, D. G., & Brekken, R. A. (2009). Cytokine levels correlate with immune cell infiltration after anti-VEGF therapy in preclinical mouse models of breast cancer. PLoS ONE, 4(11), e7669.
Ruotsalainen, J., Martikainen, M., Niittykoski, M., Huhtala, T., Aaltonen, T., Heikkila, J., Bell, J., Vaha-Koskela, M., & Hinkkanen, A. (2012). Interferon-beta sensitivity of tumor cells correlates with poor response to VA7 virotherapy in mouse glioma models. Molecular Therapy: The Journal of the American Society of Gene Therapy, 20(8), 1529–1539.
Ruotsalainen, J. J., Kaikkonen, M. U., Niittykoski, M., Martikainen, M. W., Lemay, C. G., Cox, J., De Silva, N. S., Kus, A., Falls, T. J., Diallo, J. S., Le Boeuf, F., Bell, J. C., Yla-Herttuala, S., Hinkkanen, A. E., & Vaha-Koskela, M. J. (2015). Clonal variation in interferon response determines the outcome of oncolytic virotherapy in mouse CT26 colon carcinoma model. Gene Therapy, 22(1), 65–75.
Russell, S. J., & Peng, K. W. (2007). Viruses as anticancer drugs. Trends in Pharmacological Sciences, 28(7), 326–333.
Russell, S. J., Peng, K. W., & Bell, J. C. (2012). Oncolytic virotherapy. Nature Biotechnology, 30(7), 658–670.
Sanford, K. K., Earle, W. R., & Likely, G. D. (1948). The growth in vitro of single isolated tissue cells. Journal of the National Cancer Institute, 9(3), 229–246.
Senzer, N. N., Kaufman, H. L., Amatruda, T., Nemunaitis, M., Reid, T., Daniels, G., Gonzalez, R., Glaspy, J., Whitman, E., Harrington, K., Goldsweig, H., Marshall, T., Love, C., Coffin, R., & Nemunaitis, J. J. (2009). Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 27(34), 5763–5771.
Shashkova, E. V., Kuppuswamy, M. N., Wold, W. S., & Doronin, K. (2008). Anticancer activity of oncolytic adenovirus vector armed with IFN-alpha and ADP is enhanced by pharmacologically controlled expression of TRAIL. Cancer Gene Therapy, 15(2), 61–72.
Sheridan, C. (2015). IDO inhibitors move center stage in immuno-oncology. Nature Biotechnology, 33(4), 321–322.
Shin, E. J., Wanna, G. B., Choi, B., Aguila, D., 3rd, Ebert, O., Genden, E. M., & Woo, S. L. (2007). Interleukin-12 expression enhances vesicular stomatitis virus oncolytic therapy in murine squamous cell carcinoma. The Laryngoscope, 117(2), 210–214.
Sinkovics, J. G. (1991). Viral oncolysates as human tumor vaccines. International Reviews of Immunology, 7(4), 259–287.
Sinkovics, J. G., & Horvath, J. C. (2006). Evidence accumulating in support of cancer vaccines combined with chemotherapy: A pragmatic review of past and present efforts. International Journal of Oncology, 29(4), 765–777.
Skelding, K. A., Barry, R. D., & Shafren, D. R. (2012). Enhanced oncolysis mediated by Coxsackievirus A21 in combination with doxorubicin hydrochloride. Investigational New Drugs, 30(2), 568–581.
Smakman, N., van der Bilt, J. D., van den Wollenberg, D. J., Hoeben, R. C., Borel Rinkes, I. H., & Kranenburg, O. (2006). Immunosuppression promotes reovirus therapy of colorectal liver metastases. Cancer Gene Therapy, 13(8), 815–818.
Small, E. J., Carducci, M. A., Burke, J. M., Rodriguez, R., Fong, L., van Ummersen, L., Yu, D. C., Aimi, J., Ando, D., Working, P., Kirn, D., & Wilding, G. (2006). A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Molecular Therapy: The Journal of the American Society of Gene Therapy, 14(1), 107–117.
Sobol, P. T., Boudreau, J. E., Stephenson, K., Wan, Y., Lichty, B. D., & Mossman, K. L. (2011). Adaptive antiviral immunity is a determinant of the therapeutic success of oncolytic virotherapy. Molecular Therapy: The Journal of the American Society of Gene Therapy, 19(2), 335–344.
Southam, C. M. (1960). Present status of oncolytic virus studies. Transactions of the New York Academy of Sciences, 22, 657–673.
Southam, C. M., & Moore, A. E. (1952). Clinical studies of viruses as antineoplastic agents with particular reference to Egypt 101 virus. Cancer, 5(5), 1025–1034.
Sova, P., Ren, X. W., Ni, S., Bernt, K. M., Mi, J., Kiviat, N., & Lieber, A. (2004). A tumor-targeted and conditionally replicating oncolytic adenovirus vector expressing TRAIL for treatment of liver metastases. Molecular Therapy: The Journal of the American Society of Gene Therapy, 9(4), 496–509.
Stanford, M. M., Barrett, J. W., Gilbert, P. A., Bankert, R., & McFadden, G. (2007). Myxoma virus expressing human interleukin-12 does not induce myxomatosis in European rabbits. Journal of Virology, 81(22), 12704–12708.
Stephenson, K. B., Barra, N. G., Davies, E., Ashkar, A. A., & Lichty, B. D. (2012). Expressing human interleukin-15 from oncolytic vesicular stomatitis virus improves survival in a murine metastatic colon adenocarcinoma model through the enhancement of anti-tumor immunity. Cancer Gene Therapy, 19(4), 238–246.
Stojdl, D. F., Lichty, B., Knowles, S., Marius, R., Atkins, H., Sonenberg, N., & Bell, J. C. (2000). Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nature Medicine, 6(7), 821–825.
Stojdl, D. F., Lichty, B. D., tenOever, B. R., Paterson, J. M., Power, A. T., Knowles, S., Marius, R., Reynard, J., Poliquin, L., Atkins, H., Brown, E. G., Durbin, R. K., Durbin, J. E., Hiscott, J., & Bell, J. C. (2003). VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell, 4(4), 263–275.
Su, C., Peng, L., Sham, J., Wang, X., Zhang, Q., Chua, D., Liu, C., Cui, Z., Xue, H., Wu, H., Yang, Q., Zhang, B., Liu, X., Wu, M., & Qian, Q. (2006). Immune gene-viral therapy with triplex efficacy mediated by oncolytic adenovirus carrying an interferon-gamma gene yields efficient antitumor activity in immunodeficient and immunocompetent mice. Molecular Therapy: The Journal of the American Society of Gene Therapy, 13(5), 918–927.
Suskind, R. G., Huebner, R. J., Rowe, W. P., & Love, R. (1957). Viral agents oncolytic for human tumors in heterologous host; oncolytic effect of Coxsackie B viruses. Proceedings of the Society for Experimental Biology and Medicine Society for Experimental Biology and Medicine, 94(2), 309–318.
Takakuwa, H., Goshima, F., Nozawa, N., Yoshikawa, T., Kimata, H., Nakao, A., Nawa, A., Kurata, T., Sata, T., & Nishiyama, Y. (2003). Oncolytic viral therapy using a spontaneously generated herpes simplex virus type 1 variant for disseminated peritoneal tumor in immunocompetent mice. Archives of Virology, 148(4), 813–825.
Takeuchi, O., & Akira, S. (2010). Pattern recognition receptors and inflammation. Cell, 140(6), 805–820.
Tang, D., Kang, R., Coyne, C. B., Zeh, H. J., & Lotze, M. T. (2012). PAMPs and DAMPs: Signal 0s that spur autophagy and immunity. Immunological Reviews, 249(1), 158–175.
Taqi, A. M., Abdurrahman, M. B., Yakubu, A. M., & Fleming, A. F. (1981). Regression of Hodgkin’s disease after measles. Lancet, 1(8229), 1112.
Terada, K., Wakimoto, H., Tyminski, E., Chiocca, E. A., & Saeki, Y. (2006). Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models. Gene Therapy, 13(8), 705–714.
Tesniere, A., Panaretakis, T., Kepp, O., Apetoh, L., Ghiringhelli, F., Zitvogel, L., & Kroemer, G. (2008). Molecular characteristics of immunogenic cancer cell death. Cell Death and Differentiation, 15(1), 3–12.
Todo, T., Martuza, R. L., Dallman, M. J., & Rabkin, S. D. (2001). In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity. Cancer Research, 61(1), 153–161.
Tomita, K., Sakurai, F., Tachibana, M., & Mizuguchi, H. (2012). Correlation between adenovirus-neutralizing antibody titer and adenovirus vector-mediated transduction efficiency following intratumoral injection. Anticancer Research, 32(4), 1145–1152.
Tong, Y., Zhu, W., Huang, X., You, L., Han, X., Yang, C., & Qian, W. (2014). PI3K inhibitor LY294002 inhibits activation of the Akt/mTOR pathway induced by an oncolytic adenovirus expressing TRAIL and sensitizes multiple myeloma cells to the oncolytic virus. Oncology Reports, 31(4), 1581–1588.
Touchefeu, Y., Vassaux, G., & Harrington, K. J. (2011). Oncolytic viruses in radiation oncology. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology, 99(3), 262–270.
Tsai, Y. S., Shiau, A. L., Chen, Y. F., Tsai, H. T., Tzai, T. S., & Wu, C. L. (2010). Enhancement of antitumor activity of gammaretrovirus carrying IL-12 gene through genetic modification of envelope targeting HER2 receptor: A promising strategy for bladder cancer therapy. Cancer Gene Therapy, 17(1), 37–48.
Vacchelli, E., Eggermont, A., Sautes-Fridman, C., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013). Trial watch: Oncolytic viruses for cancer therapy. Oncoimmunology, 2(6), e24612.
Vaha-Koskela, M. J., Le Boeuf, F., Lemay, C., De Silva, N., Diallo, J. S., Cox, J., Becker, M., Choi, Y., Ananth, A., Sellers, C., Breton, S., Roy, D., Falls, T., Brun, J., Hemminki, A., Hinkkanen, A., & Bell, J. C. (2013). Resistance to two heterologous neurotropic oncolytic viruses, Semliki Forest virus and vaccinia virus, in experimental glioma. Journal of Virology, 87(4), 2363–2366.
van Elsas, A., Hurwitz, A. A., & Allison, J. P. (1999). Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. The Journal of Experimental Medicine, 190(3), 355–366.
van Rikxoort, M., Michaelis, M., Wolschek, M., Muster, T., Egorov, A., Seipelt, J., Doerr, H. W., & Cinatl, J., Jr. (2012). Oncolytic effects of a novel influenza A virus expressing interleukin-15 from the NS reading frame. PLoS ONE, 7(5), e36506.
Varghese, S., Rabkin, S. D., Liu, R., Nielsen, P. G., Ipe, T., & Martuza, R. L. (2006). Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers. Cancer Gene Therapy, 13(3), 253–265.
Vigil, A., Park, M. S., Martinez, O., Chua, M. A., Xiao, S., Cros, J. F., Martinez-Sobrido, L., Woo, S. L., & Garcia-Sastre, A. (2007). Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus. Cancer Research, 67(17), 8285–8292.
Vincent, J., Mignot, G., Chalmin, F., Ladoire, S., Bruchard, M., Chevriaux, A., Martin, F., Apetoh, L., Rebe, C., & Ghiringhelli, F. (2010). 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Research, 70(8), 3052–3061.
Wakimoto, H., Fulci, G., Tyminski, E., & Chiocca, E. A. (2004). Altered expression of antiviral cytokine mRNAs associated with cyclophosphamide’s enhancement of viral oncolysis. Gene Therapy, 11(2), 214–223.
Wang, Z. G., Zhao, W., Ramachandra, M., & Seth, P. (2006). An oncolytic adenovirus expressing soluble transforming growth factor-beta type II receptor for targeting breast cancer: In vitro evaluation. Molecular Cancer Therapeutics, 5(2), 367–373.
Wang, L. C., Lynn, R. C., Cheng, G., Alexander, E., Kapoor, V., Moon, E. K., Sun, J., Fridlender, Z. G., Isaacs, S. N., Thorne, S. H., & Albelda, S. M. (2012). Treating tumors with a vaccinia virus expressing IFNbeta illustrates the complex relationships between oncolytic ability and immunogenicity. Molecular Therapy: The Journal of the American Society of Gene Therapy, 20(4), 736–748.
Washburn, B., & Schirrmacher, V. (2002). Human tumor cell infection by Newcastle Disease Virus leads to upregulation of HLA and cell adhesion molecules and to induction of interferons, chemokines and finally apoptosis. International Journal of Oncology, 21(1), 85–93.
Webb, H. E., & Smith, C. E. (1970). Viruses in the treatment of cancer. Lancet, 1(7658), 1206–1208.
Weller, T. H., Robbins, F. C., & Enders, J. F. (1949). Cultivation of poliomyelitis virus in cultures of human foreskin and embryonic tissues. Proceedings of the Society for Experimental Biology and Medicine Society for Experimental Biology and Medicine, 72(1), 153–155.
Weng, M., Gong, W., Ma, M., Chu, B., Qin, Y., Zhang, M., Lun, X., McFadden, G., Forsyth, P., Yang, Y., & Quan, Z. (2014). Targeting gallbladder cancer: Oncolytic virotherapy with myxoma virus is enhanced by rapamycin in vitro and further improved by hyaluronan in vivo. Molecular Cancer, 13, 82.
Wennier, S. T., Liu, J., & McFadden, G. (2012). Bugs and drugs: Oncolytic virotherapy in combination with chemotherapy. Current Pharmaceutical Biotechnology, 13(9), 1817–1833.
Willmon, C. L., Saloura, V., Fridlender, Z. G., Wongthida, P., Diaz, R. M., Thompson, J., Kottke, T., Federspiel, M., Barber, G., Albelda, S. M., & Vile, R. G. (2009). Expression of IFN-beta enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma. Cancer Research, 69(19), 7713–7720.
Wohlfahrt, M. E., Beard, B. C., Lieber, A., & Kiem, H. P. (2007). A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models. Cancer Research, 67(18), 8783–8790.
Wongthida, P., Diaz, R. M., Galivo, F., Kottke, T., Thompson, J., Pulido, J., Pavelko, K., Pease, L., Melcher, A., & Vile, R. (2010). Type III IFN interleukin-28 mediates the antitumor efficacy of oncolytic virus VSV in immune-competent mouse models of cancer. Cancer Research, 70(11), 4539–4549.
Workenhe, S. T., Pol, J. G., Lichty, B. D., Cummings, D. T., & Mossman, K. L. (2013). Combining oncolytic HSV-1 with immunogenic cell death-inducing drug mitoxantrone breaks cancer immune tolerance and improves therapeutic efficacy. Cancer Immunology Research, 1(5), 309–319.
Workenhe, S. T., Simmons, G., Pol, J. G., Lichty, B. D., Halford, W. P., & Mossman, K. L. (2014). Immunogenic HSV-mediated oncolysis shapes the antitumor immune response and contributes to therapeutic efficacy. Molecular Therapy: The Journal of the American Society of Gene Therapy, 22(1), 123–131.
Wuest, T. R., & Carr, D. J. (2010). VEGF-A expression by HSV-1-infected cells drives corneal lymphangiogenesis. The Journal of Experimental Medicine, 207(1), 101–115.
Wuest, T., Zheng, M., Efstathiou, S., Halford, W. P., & Carr, D. J. (2011). The herpes simplex virus-1 transactivator infected cell protein-4 drives VEGF-A dependent neovascularization. PLoS Pathogens, 7(10), e1002278.
Xia, Z. J., Chang, J. H., Zhang, L., Jiang, W. Q., Guan, Z. Z., Liu, J. W., Zhang, Y., Hu, X. H., Wu, G. H., Wang, H. Q., Chen, Z. C., Chen, J. C., Zhou, Q. H., Lu, J. W., Fan, Q. X., Huang, J. J., & Zheng, X. (2004). Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus. Ai zheng = Aizheng = Chinese Journal of Cancer, 23(12), 1666–1670.
Xu, R. H., Yuan, Z. Y., Guan, Z. Z., Cao, Y., Wang, H. Q., Hu, X. H., Feng, J. F., Zhang, Y., Li, F., Chen, Z. T., Wang, J. J., Huang, J. J., Zhou, Q. H., & Song, S. T. (2003). Phase II clinical study of intratumoral H101, an E1B deleted adenovirus, in combination with chemotherapy in patients with cancer. Ai zheng = Aizheng = Chinese Journal of Cancer, 22(12), 1307–1310.
Yaacov, B., Eliahoo, E., Lazar, I., Ben-Shlomo, M., Greenbaum, I., Panet, A., & Zakay-Rones, Z. (2008). Selective oncolytic effect of an attenuated Newcastle disease virus (NDV-HUJ) in lung tumors. Cancer Gene Therapy, 15(12), 795–807.
Yan, Y., Li, S., Jia, T., Du, X., Xu, Y., Zhao, Y., Li, L., Liang, K., Liang, W., Sun, H., & Li, R. (2015). Combined therapy with CTL cells and oncolytic adenovirus expressing IL-15-induced enhanced antitumor activity. Tumour Biology: The Journal of the International Society for Oncodevelopmental Biology and Medicine, 36(6), 4535–4543.
Yang, Y. F., Xue, S. Y., Lu, Z. Z., Xiao, F. J., Yin, Y., Zhang, Q. W., Wu, C. T., Wang, H., & Wang, L. S. (2014). Antitumor effects of oncolytic adenovirus armed with PSA-IZ-CD40L fusion gene against prostate cancer. Gene Therapy, 21(8), 723–731.
Ye, X., Lu, Q., Zhao, Y., Ren, Z., Ren, X. W., Qiu, Q. H., Tong, Y., Liang, M., Hu, F., & Chen, H. Z. (2005). Conditionally replicative adenovirus vector carrying TRAIL gene for enhanced oncolysis of human hepatocellular carcinoma. International Journal of Molecular Medicine, 16(6), 1179–1184.
Yohn, D. S., Hammon, W. M., Atchison, R. W., & Casto, B. C. (1968). Oncolytic potentials of nonhuman viruses for human cancer. II. Effects of five viruses on heterotransplantable human tumors. Journal of the National Cancer Institute, 41(2), 523–529.
Yoo, J. Y., Ryu, J., Gao, R., Yaguchi, T., Kaul, S. C., Wadhwa, R., & Yun, C. O. (2010). Tumor suppression by apoptotic and anti-angiogenic effects of mortalin-targeting adeno-oncolytic virus. The Journal of Gene Medicine, 12(7), 586–595.
Yu, W., & Fang, H. (2007). Clinical trials with oncolytic adenovirus in China. Current Cancer Drug Targets, 7(2), 141–148.
Yu, D. C., Chen, Y., Dilley, J., Li, Y., Embry, M., Zhang, H., Nguyen, N., Amin, P., Oh, J., & Henderson, D. R. (2001). Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel. Cancer Research, 61(2), 517–525.
Yu, F., Wang, X., Guo, Z. S., Bartlett, D. L., Gottschalk, S. M., & Song, X. T. (2014). T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy. Molecular Therapy: The Journal of the American Society of Gene Therapy, 22(1), 102–111.
Yuan, Z. Y., Zhang, L., Li, S., Qian, X. Z., & Guan, Z. Z. (2003). Safety of an E1B deleted adenovirus administered intratumorally to patients with cancer. Ai zheng = Aizheng = Chinese journal of cancer, 22(3), 310–313.
Zamarin, D., Martinez-Sobrido, L., Kelly, K., Mansour, M., Sheng, G., Vigil, A., Garcia-Sastre, A., Palese, P., & Fong, Y. (2009a). Enhancement of oncolytic properties of recombinant newcastle disease virus through antagonism of cellular innate immune responses. Molecular Therapy: The Journal of the American Society of Gene Therapy, 17(4), 697–706.
Zamarin, D., Vigil, A., Kelly, K., Garcia-Sastre, A., & Fong, Y. (2009b). Genetically engineered Newcastle disease virus for malignant melanoma therapy. Gene Therapy, 16(6), 796–804.
Zamarin, D., Holmgaard, R. B., Subudhi, S. K., Park, J. S., Mansour, M., Palese, P., Merghoub, T., Wolchok, J. D., & Allison, J. P. (2014). Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Science Translational Medicine, 6(226), 226ra232.
Zhang, W. W., Alemany, R., Wang, J., Koch, P. E., Ordonez, N. G., & Roth, J. A. (1995). Safety evaluation of Ad5CMV-p53 in vitro and in vivo. Human Gene Therapy, 6(2), 155–164.
Zhang, J., Ramesh, N., Chen, Y., Li, Y., Dilley, J., Working, P., & Yu, D. C. (2002). Identification of human uroplakin II promoter and its use in the construction of CG8840, a urothelium-specific adenovirus variant that eliminates established bladder tumors in combination with docetaxel. Cancer Research, 62(13), 3743–3750.
Zhang, L., Dermawan, K., Jin, M., Liu, R., Zheng, H., Xu, L., Zhang, Y., Cai, Y., Chu, Y., & Xiong, S. (2008). Differential impairment of regulatory T cells rather than effector T cells by paclitaxel-based chemotherapy. Clinical Immunology, 129(2), 219–229.
Zhang, Q., Liang, C., Yu, Y. A., Chen, N., Dandekar, T., & Szalay, A. A. (2009). The highly attenuated oncolytic recombinant vaccinia virus GLV-1h68: Comparative genomic features and the contribution of F14.5L inactivation. Molecular Genetics and Genomics: MGG, 282(4), 417–435.
Zhang, Z., Hu, Z., Gupta, J., Krimmel, J. D., Gerseny, H. M., Berg, A. F., Robbins, J. S., Du, H., Prabhakar, B., & Seth, P. (2012). Intravenous administration of adenoviruses targeting transforming growth factor beta signaling inhibits established bone metastases in 4T1 mouse mammary tumor model in an immunocompetent syngeneic host. Cancer Gene Therapy, 19(9), 630–636.
Zhang, W., Fulci, G., Wakimoto, H., Cheema, T. A., Buhrman, J. S., Jeyaretna, D. S., Stemmer Rachamimov, A. O., Rabkin, S. D., & Martuza, R. L. (2013). Combination of oncolytic herpes simplex viruses armed with angiostatin and IL-12 enhances antitumor efficacy in human glioblastoma models. Neoplasia, 15(6), 591–599.
Zhang, W., Ge, K., Zhao, Q., Zhuang, X., Deng, Z., Liu, L., Li, J., Zhang, Y., Dong, Y., Zhang, Y., Zhang, S., & Liu, B. (2015). A novel oHSV-1 targeting telomerase reverse transcriptase-positive cancer cells via tumor-specific promoters regulating the expression of ICP4. Oncotarget, 6(24), 20345–20355.
Zhao, H., Janke, M., Fournier, P., & Schirrmacher, V. (2008). Recombinant Newcastle disease virus expressing human interleukin-2 serves as a potential candidate for tumor therapy. Virus Research, 136(1–2), 75–80.
Zhao, Q., Zhang, W., Ning, Z., Zhuang, X., Lu, H., Liang, J., Li, J., Zhang, Y., Dong, Y., Zhang, Y., Zhang, S., Liu, S., & Liu, B. (2014). A novel oncolytic herpes simplex virus type 2 has potent anti-tumor activity. PLoS ONE, 9(3), e93103.
Zheng, J. N., Pei, D. S., Sun, F. H., Liu, X. Y., Mao, L. J., Zhang, B. F., Wen, R. M., Xu, W., Shi, Z., Liu, J. J., & Li, W. (2009). Potent antitumor efficacy of interleukin-18 delivered by conditionally replicative adenovirus vector in renal cell carcinoma-bearing nude mice via inhibition of angiogenesis. Cancer Biology & Therapy, 8(7), 599–606.
Zhu, W., Zhang, H., Shi, Y., Song, M., Zhu, B., & Wei, L. (2013). Oncolytic adenovirus encoding tumor necrosis factor-related apoptosis inducing ligand (TRAIL) inhibits the growth and metastasis of triple-negative breast cancer. Cancer Biology & Therapy, 14(11), 1016–1023.
Zhuang, X., Zhang, W., Chen, Y., Han, X., Li, J., Zhang, Y., Zhang, Y., Zhang, S., & Liu, B. (2012). Doxorubicin-enriched, ALDH(br) mouse breast cancer stem cells are treatable to oncolytic herpes simplex virus type 1. BMC Cancer, 12, 549.
Zygiert, Z. (1971). Hodgkin’s disease: Remissions after measles. Lancet, 1(7699), 593.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Tsun, A., Miao, X.N., Wang, C.M., Yu, D.C. (2016). Oncolytic Immunotherapy for Treatment of Cancer. In: Zhang, S. (eds) Progress in Cancer Immunotherapy. Advances in Experimental Medicine and Biology, vol 909. Springer, Dordrecht. https://doi.org/10.1007/978-94-017-7555-7_5
Download citation
DOI: https://doi.org/10.1007/978-94-017-7555-7_5
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-017-7553-3
Online ISBN: 978-94-017-7555-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)